A NATURE-INSPIRED SOLUTION TO TRAP PATHOGENS
AIS Biotech (where AIS stands for Anti Infective Sugar) is a French biotech company created in March 2023, intending to develop a new class of sugar-based anti-infective biotherapeutics. They act as decoy receptors that prevent the attachment of pathogens to epithelial cell surface sugars.
a sustainable bioengineered platform
a sustainable bioENGINEERED plateform to produce tailor-made sugars
Many viruses and bacteria bind to mammalian cells by recognizing specific oligosaccharide ligands. By mimicking cell receptors, glycomimetics can be used to prevent the binding of pathogens to host cell surface and neutralize the infection.
our biotechnological process paves the way for the development of a pipeline of anti-infective biotherapeutics
Beyond GLYCOFLU, AIS Biotech aims to develop a pipeline of new anti-infective sugar-based therapies.
glycoflu
eco-friendly bioproduct
GlycoFlu is made of oligosaccharides structurally close to natural cell surface sugars
Promising antiviral activity
GlycoFlu is our first preclinical-stage drug candidate targeting A and B Influenza viruses
To Meet a global medical need
High risk that one of the next pandemics could be caused by an influenza virus strain whereas any treatments are suitable yet
Therapeutic use
The nasal administration is particularly suitable for young children, the elderly, and immunocompromised people who are at high risk of flu complications
our strategic road map
research
Preclinical development
bioprocess scale-up
Clinical proof of concept
Because our footprint is at the heart of our concerns,
we invest in environmental, social, and societal factors:
societal
The Covid-19 pandemic has demonstrated how the world could be destabilized by an emerging virus leading to considerable health, social and economic consequences. With the aim of developing a new therapeutic class of biomedicines, AIS Biotech strives for the fight against infectious diseases.
environmental
Reducing our environmental impact is a value held by the company. By preserving natural resources, reducing costs, and accelerating the development of greener products, AIS Biotech with its bioproduction process, contributes to sustainable practices. Our technological platform allows us to move away from petrosourced chemistry.
social & governance
We advocate fair and equitable governance with gender equality, and we want a inclusive company representative of the diversity of the society. We are paying attention to good working conditions. A clear and transparent communication, integrity, collaboration and ethical behavior in all actions and decisions are core values of the company.
To develop its technology, AIS Biotech is supported by a strong and structured network of partners
AIS Biotech est co-financé par l’Union Européenne dans le cadre du Fonds Européen de Développement Régional (FEDER).